Short Interest in Curanex Pharmaceuticals Inc (NASDAQ:CURX) Declines By 38.0%

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 20,835 shares, a decrease of 38.0% from the June 15th total of 33,610 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 77,001 shares, the short-interest ratio is currently 0.3 days.

Curanex Pharmaceuticals Stock Down 0.1%

Shares of CURX stock opened at $0.22 on Friday. The firm has a 50 day moving average of $0.29 and a 200-day moving average of $0.36. The company has a market cap of $6.18 million and a price-to-earnings ratio of -0.80. Curanex Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $9.18.

Curanex Pharmaceuticals (NASDAQ:CURX) last issued its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Curanex Pharmaceuticals presently has a consensus rating of “Sell”.

Institutional Trading of Curanex Pharmaceuticals

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.